The EPS miss is mechanical for a pre-revenue biotech scaling R&D ahead of a pivotal trial. The critical catalyst is the FDA-aligned Phase 3 design for EB613—monitor for enrollment updates, interim data, and any financing needs (cash burn likely to increase).
Price Chart
Executive Summary
Entera Bio reported Q2 2026 EPS of $-0.14, a 75% miss versus the $-0.08 consensus, though the company highlighted FDA alignment on a 12-month registrational Phase 3 study for EB613. The wide EPS miss, in a pre-revenue clinical-stage biotech, likely reflects increased R&D spend ahead of the pivotal trial, but the regulatory milestone supports the drug's path to NDA.
Key Financial Metrics
Key Facts
- Q2 2026 EPS: $-0.14 vs consensus $-0.08 (-75% miss)
- Revenue: $0 (pre-revenue clinical-stage company)
- FDA alignment on 12-month registrational Phase 3 study to support NDA for EB613
- EB613 is the first oral anabolic tablet in development for postmenopausal osteoporosis
Financial Impact
EPS miss of $-0.14 vs $-0.08; no revenue reported
Risk Factors
- Clinical trial risk: Phase 3 failure could eliminate the pipeline value
- Dilution risk: pre-revenue company may need capital to fund the Phase 3 study
- Regulatory risk: FDA alignment does not guarantee positive Phase 3 results or eventual NDA approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341389 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $2.84 | awaiting T+60 | — | $3.06 (+7.75%) |
Oct 14, 2026 13d ago | DEF 14A | $2.77 | awaiting T+60 | — | $3.06 (+10.47%) |
Oct 6, 2026 21d ago | 8-K | $2.53 | awaiting T+60 | — | $3.06 (+20.95%) |
Aug 27, 2026 8w ago | Press Release | $3.08 | awaiting T+60 | — | $3.06 (−0.65%) |
Aug 18, 2026 10w ago | 8-K | $2.89 | awaiting T+60 | — | $3.06 (+5.88%) |
Aug 7, 2026 11w ago | Press Release | $3.04 | awaiting T+60 | — | $3.06 (+0.66%) |
Jul 29, 2026 12w ago | Press Release | $3.00 $3.02 | ▲ +0.67% | ▼ −4.06% | $3.06 (+2.00%) |
Jun 16, 2026 19w ago | Press Release | $1.18 $2.79 | ▲ +136.44% | ▲ +135.44% | $3.06 (+159.32%) |
May 28, 2026 21w ago | Press Release | $1.22 $3.23 | ▲ +164.75% | ▲ +163.02% | $3.06 (+150.82%) |
May 18, 2026 23w ago | EFFECT | $1.23 $2.80 | ▲ +127.64% | ▲ +122.79% | $3.06 (+148.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers